{"nctId":"NCT02886715","briefTitle":"A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris","startDateStruct":{"date":"2016-09-21","type":"ACTUAL"},"conditions":["Acne Vulgaris"],"count":1110,"armGroups":[{"label":"Test","type":"EXPERIMENTAL","interventionNames":["Drug: Tazarotene Cream 0.1%"]},{"label":"Reference","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tazorac®"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Tazarotene Cream 0.1%","otherNames":["Tazarotene"]},{"name":"Tazorac®","otherNames":["Tazarotene"]},{"name":"Placebo","otherNames":["Vehicle"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy male or non-pregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis of acne vulgaris.\n* Must have a minimum of ≥ 25 non-inflammatory lesions and ≥ 20 inflammatory lesions and ≤ 2 nodulocystic lesions at baseline on the face.\n* Must have a definite clinical diagnosis of acne vulgaris severity grade 2, 3, or 4 as per the Investigator's Global Assessment.\n\nExclusion Criteria:\n\n* Female subjects who are pregnant, nursing or planning to become pregnant during study participation.\n* Have a history of hypersensitivity or allergy to tazarotene, retinoids and/or any of the study medication ingredients.\n* Presence of any skin condition that would interfere with the diagnosis or assessment of acne vulgaris.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"40 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Inflammatory Lesion Counts","description":"Percent change from baseline to week 12 in the inflammatory (papules and pustules) lesion counts","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-58.44","spread":"1.33"},{"groupId":"OG001","value":"-60.07","spread":"1.32"},{"groupId":"OG002","value":"-53.28","spread":"1.81"}]}]}]},{"type":"SECONDARY","title":"Clinical Response of Success","description":"The proportion of subjects with a clinical response of success at week 12, success defined as an Investigator's Global Assessment score that is at least two grades less than the baseline assessment","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"23.7","spread":null},{"groupId":"OG002","value":"15.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Change in Non-inflammatory Lesion Counts","description":"Percent change from baseline to week 12 in the non-inflammatory (open and closed comedones) lesion counts","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-50.11","spread":"1.27"},{"groupId":"OG001","value":"-51.99","spread":"1.26"},{"groupId":"OG002","value":"-45.72","spread":"1.73"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":442},"commonTop":["Application site dryness","Application site pain","Application site pruritus","Nasopharyngitis","Application site exfoliation"]}}}